Brunel V, Sainty D, Costello R, Mozziconacci M J, Simonetti J, Arnoulet C, Coignet L, Bouabdallah R, Gastaut J A, Gabert J
Department of Biology, Institut Paoli-Calmettes, Marseille, France.
Cancer Genet Cytogenet. 1995 Nov;85(1):82-4. doi: 10.1016/0165-4608(95)00140-9.
We report the case of a patient having Philadelphia-negative, bcr-abl-positive chronic myeloid leukemia. In situ hybridization showed the presence of the bcr-abl fusion on the chromosome 9 long arm in all mitoses observed. Stability of the disease was very difficult to obtain because of serious adverse effects to interferon and chemotherapy, mainly grade IV neutropenia, and a blast crisis occurred 12 months after diagnosis. Only three other patients with such presentation (Philadelphia negative, bcr-abl positive with bcr-abl fusion on the chromosome 9 long arm) have been reported, with a poor therapeutic response and outcome in two of them. Translocation of BCR to chromosome 9 may therefore have a worse prognosis than translocation of ABL to chromosome 22 in Philadelphia-negative chronic myeloid leukemia.
我们报告了一例费城染色体阴性、bcr-abl阳性的慢性髓性白血病患者。原位杂交显示，在所有观察到的有丝分裂中，9号染色体长臂上均存在bcr-abl融合基因。由于对干扰素和化疗有严重不良反应，主要是IV级中性粒细胞减少，很难实现疾病稳定，且在诊断后12个月发生了急变期。仅另有3例有此表现（费城染色体阴性、bcr-abl阳性且9号染色体长臂上有bcr-abl融合基因）的患者被报道，其中2例治疗反应和结局不佳。因此，在费城染色体阴性的慢性髓性白血病中，BCR易位至9号染色体可能比ABL易位至22号染色体的预后更差。
